University of Central Florida

STARS
Electronic Theses and Dissertations, 2004-2019
2007

Synthesis Of Novel Aziridine Derivatives Of Podocarpic Acid
Stephen Rhoden
University of Central Florida

Part of the Chemistry Commons

Find similar works at: https://stars.library.ucf.edu/etd
University of Central Florida Libraries http://library.ucf.edu
This Masters Thesis (Open Access) is brought to you for free and open access by STARS. It has been accepted for
inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

STARS Citation
Rhoden, Stephen, "Synthesis Of Novel Aziridine Derivatives Of Podocarpic Acid" (2007). Electronic Theses
and Dissertations, 2004-2019. 3316.
https://stars.library.ucf.edu/etd/3316

SYNTHESIS OF NOVEL
AZIRIDINE DERIVATIVES
OF PODOCARPIC ACID

by

STEPHEN RHODEN
B.S. University of the West Indies, 2003

A thesis submitted in partial fulfillment of the requirements
for the degree of Master of Science
in the Department of Chemistry
in the College of Sciences
at the University of Central Florida
Orlando, Florida

Summer Term
2007

© 2007 Stephen Rhoden

ii

ABSTRACT

Podocarpic acid (a diterpenoid resin acid extracted from the Podocarpacea specie of
plants) has shown cytotoxicity against carcinoma of the nasopharynx. Since this discovery has
been made, research has been performed in order to alter the structure of the resin acid so as to
increase the anticancer activity. The carboxylic acid and phenol functional groups, which are
present in podocarpic acid, make it possible to synthesize new derivatives selectively at the C-15,
C-13, and C-7 positions as well as by substitution of the phenol hydroxyl group. Thus numerous
derivatives can be prepared, in high yield, for the purpose of investigating their potential, as new
drug leads for the treatment of cancer. In this study, Doyle’s catalyst (Dirhodium tetrakis
caprolactamate) was used to form a novel derivative in high yield (85%) which contained a 3membered aziridine ring at the C-6 and C-7 position. The main thrust of this research involved
the formation a series of novel derivatives of the aziridine compound by utilizing phenol and mchlorophenol as nucleophiles to open the aziridine ring. These novel compounds will now be
sent to the National Institute of Health (NIH) for bioassay against 60 human cancer cell lines.
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For dad, Alvan Douglas Rhoden, who passed away in summer 2006.
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1.0. INTRODUCTION
1.1. Cancer

Cancer development (carcinogenesis) occurs when human cells begin to grow out
1

of control . A normal cell is believed to be transformed into a cancerous cell through
many stages over a number of years or even decades. Normally, cells in the body grow,
divide and then die in a regular cycle. An adult normally produces cells only when they
need to be replaced, due to cell death or injury. Cancer tends to form when a carcinogen,
such as free radical ions or radiation, and DNA of tissue cells react and as a result the
cancerous cells replicate, and in most cases, form solid tumors. In some rare cases the
2

tumor is in a fluid form as in the case of leukemia .
There are two types of tumors: malignant (cancerous) and benign (noncancerous). Cancerous cells are able to travel from one area of the body to another via the
blood or other fluids. Upon being transported to another section of the anatomy, the cells
begin to reproduce and replace the normal tissue. This process is called metastasis.

1.2. Treatment of Cancer

Cancer is the second leading cause of death (preceded only by cardiovascular
3

disease) in the United States . One half of the men and one third of the women in the
United States will develop cancer during their lifetimes. The risk of developing most
types of cancer can be reduced by changes in a person's lifestyle, for example, by quitting
smoking and following a better diet1. Discovering the cancer early, so that proper
1

treatments can be administered will increase the chances of a full recovery from the
disease.
The oldest and most common way of removing a cancerous tumor is by surgery.
During the surgical procedure, in which the malignant tissue is removed via a cryogenic
technique, the extent to which the cancer has spread can be diagnosed. Another way of
making the cancer benign is radiotherapy, which utilizes ionizing rays that are used to kill
cancer cells and reduce tumor size in a selected area. Chemotherapy is also a common
treatment which uses drugs that are selectively toxic to cancer cells. Chemotherapy is
used to hopefully destroy the non-visible cancerous cells that were not removed during
surgery. One problem with chemotherapy, however, is that the drugs that are used to kill
cancerous cells are also toxic to healthy cells, giving rise to side effects such as hair loss
and anemia. Thus there is urgency for the discovery of new chemotherapeutic agents for
the treatment of cancer which are more selective in their toxicity to cancer cells versus
normal healthy cells.

1.3. Natural Products for Cancer Treatment

Traditional medicine has been used worldwide for thousands of years

4,5,6

.

Traditional medicine involves the use of plant extracts (a mixture of compounds that are
soluble in water or other appropriate solvents) or a pure substance that is easy to isolate
from a plant. It is estimated by the World Health Organization, that 80% of the world’s
inhabitants rely mainly on traditional medicine for their primary health care

7,8

. As far as

the treatment of cancer is concerned, of the 92 drugs which were available commercially

2

between the years of 1983 to 1994, approximately 57 drugs (62%) can be related to a
9

natural product origin .
Natural products have been studied for thousands of years by the Chinese; their
traditional herbal medicine is an example of one large source of new drug leads. The
discovery of new drug leads from traditional medicines (natural products) involves three
main approaches which are: (a) bioactivity – or mechanism of action-directed isolation
and characterization of active compounds, (b) drug design-based modification and
analogue synthesis and (c) mechanism of action studies, including drug receptor
interactions and specific enzyme inhibitions. After selection of a new lead drug (isolation
of lead drug from natural source), drug development continues outside of academic
laboratories through preclinical studies which includes toxicology, formulation and
10

production and then finally to clinical trials .

1.4. Podocarpic Acid

Podocarpic acid (1)
Oudemans

14

11 , 12 , 13

is a natural conifer resin acid, that was isolated by

in 1873 from Podocarpus Cupressinum. It was extracted from ‘kahikatea’

tree Podocarpus Dacrydioides and from ‘rimu’ tree Dacrydium Cupressinum.

3
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Figure 1 : Structure of Podocarpic acid (1)

Figure 2 : Podocarpus Cupressinum

4

Figure 3 : Podocarpus Dacrydioides

Figure 4: Dacrydium Cupressinum

These are fast growing trees endemic to New Zealand, which is geographically shown in
Figure 5.

5

Figure 5: Distribution of Podocarpus (blue areas) in World Map

Podocarpic acid (1) is extracted with methanol from the heartwood of podocarpus
species (shown in Figure 2 and Figure 3). Podocarpic acid (1) has been used in the
pharmaceutical industry

15

16

and in the preparation of soaps, paints and adhesives .

Podocarpic acid (1) is a white solid powder with a melting point of 195oC. It has
carboxylic acid and a phenol functional group. The phenol moiety activates podocarpic
acid toward selective substitutions at either the hydroxyl, C-13 (ortho to OH), or C-7
(benzylic). Chemistry can also be performed selectively at the carboxylic acid (C-15)
position. However the chemistry that can be performed at the C-15 position is limited to
small nucleophiles (such as hydride reduction to an alcohol) due to steric hindrance from
the diaxial C-16 quaternary methyl group as shown in Figure 6: Podocarpic acid (1)
17

Conformation .

6

Figure 6: Podocarpic acid (1) Conformation

1.5. Previous Studies of Biological Active Agents from Podocarpic Acid Derivatives

Podocarpic acid and its derivatives have been shown as a source of oestrogenic
18

activity dating back to 1948 . Podocarpinol (2) as show in Figure 7 on the following is
an example of one derivative that demonstrates this type of activity.
O-R (R=H, CH3)

CH3

HOCH2

CH3

Figure 7 : Structure of Podocarpinol (2)
7

Since 1950, podocarpic acid has also been utilized in the synthesis of antiinflammatory and antiviral agents as well as other derivatives
novel compounds

22

19 , 20 , 21

. In 1993 a variety of

containing lactones (cyclic esters) and lactams (cyclic amides) were

synthesized from podocarpic acid. Two examples of compounds synthesized from
podocarpic acid are nimbiol

23

(3) and winterin

24

(4), respectively in Figures 8 and 9.

OH
CH3
CH3

O
CH3

CH3

Figure 8: Structure of Nimbiol (3)
O

O
CH3
O

CH3

CH3

Figure 9: Structure of Winterin (4)

8

Hayashi, et. al synthesized hydroxynagilactone (5) in 1982 (Figure 10) from
podocarpic acid. Compound 5 has since been shown to be a biologically active dilactone
25

(5) .
O

OH

O
CH3

CH3

CH3

CH3

O
O

Figure 10: Structure of Hydroxynagilactone (5)

In 1984 Parish and Miles reported the antitumor activity of some podocarpic acid
26

derivatives . Methyl-6α-bromo-7-oxo-O-methylpodocarpate (6), shown in Figure 11,
was reported to posses the highest level of activity against human epidermoid carcinoma
of the nasopharynx in vitro.

9

OCH3

CH3

O
H3CO2C

CH3

Br

Figure 11: Structure of Compound 6

Some 3 years later, Parish, et al also synthesized several podocarpic acid derivatives

27

demonstrating fungistatic activity. Of these derivatives, the most potent is 11,13dinitropodocarpic acid (7), the structure of which is shown below in Figure 12.
OH
O2N

NO2

CH3

HO2C

CH3

Figure 12: Structure of Compound 7
In 1997, Eli Lily and Company did a substantial amount of work on many other
new derivatives of podocarpic acid relative to attempting to find new treatments for

10

human viral infections

28 , 29 , 30

. The compounds (see Figures 13 and 14) which showed the

highest activities were isopropyl-O-methylpodocarpate (8) and methyl-O-6-en-7-oxomethylpodocarpate (9).
OCH(CH3)2

CH3

H3CO2C

CH3

Figure 13: Structure of Compound 8
OCH3

CH3

O
H3CO2C

CH3

Figure 14: Structure of Compound 9
In 1998, methyl-O-methylpodocarpate (10) (shown in Figure 15) was reported to
have antiviral properties. This work involved demonstrating that compound 10 inhibited
31

multicycle replication in protein synthesis of influenza A/Kawasaki virus .
11

OCH3

CH3

H3CO2C

CH3

Figure 15: Structure of Compound 10
In 2003, Adams, et. al., prepared podocarpic derivative 11 (Figure 16) which has
been used as an LXR agonist for treating dyslipidemic conditions such as depressed
32

levels of HDL cholesterol .
OH

CH3

H
N

CH3
O

Figure 16: Structure of Compound 11

12

In 2004, Miles and Nguyen created a novel class of amide derivatives (see general
structure 12 in Figure 17). Nguyen discovered that copper catalysts were an inexpensive
33

and efficient way of coupling aryl halides and amides . The R group in structure 12 can
be hydrogen, an alkyl group, a vinyl group or an aryl group:

OCH3

O
HN-C-R

CH3

H3CO2C

CH3

Figure 17 : General Structure of Novel Amide Derivatives (12)

1.6. Nitrogen-Containing Compounds and their Biological Activity

Two major drugs used to treat Hodgkin’s lymphoma and acute childhood
leukemia are vinblastine and vincristine. They are natural alkaloids isolated from
34

Catharanthus roseus G Don or Vinca rosea L. . Vinorelbine (13), which is a synthetic
analogue from vinblastine, has shown activity against non-small cell lung and breast
cancers, with reduced side effects. The only difference is that Navelbine (13) has a nine
membered C ring and a dehydrated D ring

35 , 36

13

.

N
N
N
H
H3CO2C

H

OH
OAc

N
H3CO

H
COOCH3

Figure 18 : Structure of Vinorelbine (Navelbine) (13)

The natural anticancer alkaloids camptothecin and 10-hydroxycamptothecin can
be isolated

37

from the Chinese tree Camptotheca (Figure 19). These alkaloids can be used

to treat gastric, rectal, colon, bladder, liver, head and neck cancers. Other synthetic
derivatives of camptothecin including topotecan and irinotecan, were used in an attempt
to solve the problem of general water insolubility of alkaloids. The water solubility of
topotecan and irinotecan is higher since they contain amino groups that are able to form
more soluble hydrochloride salts

38 , 39

.

Figure 19: Camptotheca

14

1.7. Aziridines and their Anti-tumor Activity

Aziridines are versatile intermediates that undergo a variety of synthetically
useful transformations of which nucleophilic ring opening is the most thoroughly studied.
The ring opening of aziridines, is facilitated by the release of ring strain (25-26
40

kcal/mol) . A variety of nucleophiles reveals either a primary or secondary amine when
reacted with an aziridine, hence creating a diverse range of β-substituted ethylamines.
Electron withdrawing substituents in the ring lower the pKa of the ring opened nitranion,
(hence facilitating ring opening) while electron donating groups suppress the rate of ring
opening and require harsher conditions. In this case, the closest contributing group is the
C-8 benzyl carbon on compound (10) which should have an electron withdrawing
effect

41 , 42

.

A structurally distinct class of naturally occurring aziridine derivatives possessing
biological activity (isolated from Streptomyces grieseofuscus S42227 by Nagaoka and
43

coworkers) is the Azinomycin family . These compounds possess a large range of
activity against different cancers, including solid tumors. This activity is attributed to
their ability to act as DNA cross-linking agents, similar to the mitosanes (14)

44 , 45 , 46

, via

nucleophilic ring-opening of the aziridine and epoxide moieties by N-7 positions of
purines, though it is not clear which ring opening takes precedence in the crosslinking.

15

O

O
NH2
OY

X

O
N

NZ

O

Mytocin A X=OMe, Y=Me, Z=H
Mytocin B X=OMe, Y=H, Z=Me
Porfiromycin X=NH2, Y=Me, Z=Me
Figure 20: Structure of some Mitosanes (14)

All the examples cited above illustrate the central role played by natural products in drug
development for the prevention and treatment of cancer. Compounds containing nitrogen
in the form of rings, amines and amides have been shown to enhance biological activity
against cancer and their use as pharmaceuticals

47 , 48

.

This work involves a study of the chemistry of podocarpic acid (a diterpenoid
resin acid which has shown bioactivity against cancerous tumor cells), relative to the
inclusion of an aziridine ring on the C-6 and C-7 carbon which is followed by ring
opening of the highly strained three membered ring to form novel derivatives. It is
assumed that by the introduction of nitrogen to the already biologically active podocarpic
acid, the cytotoxicity of the derivatives will also increase; and will help to continue the
search for anticancer drugs which are not toxic to normal human cells.

16

2.0 RESULTS AND DISCUSSION
As stated in the introduction, the goal of this work was to synthesize novel
derivatives of podocarpic acid by performing nucleophilic ring opening reactions on a
novel aziridine that was synthesized from podocarpic acid.
This work presents an efficient way to synthesize an aziridine derivative (18) of
podocarpic acid between the C-6 and C-7 carbon (Scheme 1) and to then to react this
highly strained 3 membered nitrogen ring further with nucleophiles (Nu) =Phenol, mchlorophenol (Scheme 2) to yield novel compounds 19 and 20. Compounds 1 to 17 were
synthesized and m.p.s IR, NMR and MS spectra were identical to those in the literature26
.

OCH3

OH

CH3

CH3

5 Steps

H

H
HOOC

H3COOC

CH3

1

CH3

18
O

Ts = Tosylate = R

S
O

Scheme 1 : Preparation of the Novel Aziridine Derivative 18

17

N

Ts

The aziridine was prepared in 5 steps from podocarpic acid. The initial reaction
was the methylation of both the phenol and carboxylic moieties on the highly insoluble
podocarpic acid (1), using dimethyl sulfate (Scheme 3), affording methyl-Omethylpodocarpate (10).
OH

OCH3

CH3

CH3

NaOH
(CH3)2SO4

H
HOOC

H

CH3

H3COOC

1

CH3

10

Scheme 2 : Formation of Methyl-O-methylpodocarpate (10)

Compound 10 had a m.p. of 1270C with a yield of 78% and the IR, NMR and MS
spectra were identical upon comparison with those of an authentic sample of methyl Omethylpodocarpate (10).

Methyl-O-methylpodocarpate (10) was then dissolved in acetic acid and was
oxidized with chromium trioxide (Scheme 4) to give methyl-O-methyl-7-ketopodocarpate
0

with m.p. 122 C and a yield of 90%. The IR, NMR and MS spectra being identical upon
comparison with that of an authentic26 sample of methyl O-methyl-7-ketopodocarpate.

18

OCH3

OCH3

CH3

CH3
CrO3
CH3COOH

O
H3COOC

CH3

H3COOC

CH3

15

10

Scheme 3 : Formation of Methyl O-methyl-7-ketopodocarpate (15)

The next step in the synthesis was the formation of the alcohol methyl O-methyl7-hydroxypodocarpate (16) in 80% yield by sodium borohydride reduction of the 7-keto
group (Scheme 5) on the C-7 atom of compound 15. The IR, NMR and MS spectra were
identical upon comparison with an authentic26 sample of methyl O-7hydroxypodocarpate.
OCH3

OCH3

CH3

CH3
NaBH4
EtOH, H2O

H
H3COOC

CH3

O

H
H3COOC

15

OH

CH3

16

Scheme 4 : Formation of Methyl-O-methyl-7-hydroxypodocarpate (16)
19

Compound 16 was then dehydrated under reflux conditions using ptoluenesulfonic acid (Scheme 6) to yield (85%) compound 17 which was isolated in pure
0

form by using flash chromatography. Pure compound 16 shown a m.p. of 84 C and the
IR, NMR and MS spectra were identical upon comparison with those of an authentic26
sample.
OCH3

OCH3

CH3

CH3
p-toluenesulfonic acid

dihydropyran

H
H3COOC

OH

H

CH3

H3COOC

16

CH3

17

Scheme 5 : Formation of Methyl-O-methyl-6,7-alkylpodocarpate (17)

The next step was an attempt to make novel aziridine derivative 18. The literature
was surveyed in an attempt to locate the most efficient procedure. Zhang et al. had
previously used iron (III) porphyrin complexes Fe(Por)Cl as effective catalysts for
aziridination of alkenes using bromamine-T as the nitrene source in 2004 49 . It was
demonstrated that different transition metals including but not limited to Mn, Fe, Ru and
Co porphyrin complexes used with bromamine-T created a catalytic aziridination system
that could be operated under mild conditions using the alkenes as limiting reagents, the
best of which was Fe(TPP)Cl system. This was abandoned when it was determined that
the bromamine-T needed would have to be prepared in vitro by bubbling bromine gas
20

through the chloramine-T and sufficient airboxes were not available to contain the
poisonous gas.
Michael P Doyle has described using a mixed valent dirhodium (II, III)
caprolactamate as a mild, selective and efficient catalyst in the aziridination of olefins 50 .
It was shown that the use of p-toluenesulfonamide, N-brmosuccinimide and potassium
carbonate readily affords aziridines in yields of up to 95% under ambient conditions with
as little as 0.01% catalyst loading. The approach involved aziridine formation occurring
5+

via Rh2 -catalyzed aminobromination. The effectiveness of the catalyst is derived from
4+

2+

its ability to undergo facile atom transfer redox chemistry (Rh2 /Rh2 ) because of its
low one-electron oxidation potential.
The direction of aziridine ring opening is mainly determined by the substrate. The
nucleophilic ring-opening (NRO) follows normal SN2 behavior, where substitution at the
least hindered side (axially or equatorially) is favored. Hou and coworkers have recently
developed a simple catalytically activated procedure that allows simple nucleophiles to
participate directly in NRO 51 . Catalytic amounts of tributylphosphine, in concert with a
nucleophile (NuH= phenol, m-chlorophenol, phenylamine) affording ring-opened
products in high yields (scheme 2).

21

R1
NR3
R1
R2
NR3

R1

NR3

NuH

R2

PBu3

R1

NR3

R2

Nu

Nu
PBu3

R2

R1

NHR3

R2

PBu3

R1

NHR3

R2

Nu

NuH

Scheme 6 : Mechanism of Aziridine Ring Opening Assisted by Tributylphosphine

Novel aziridine 18 was formed in 85% yield by reacting compound 17 in
methylene chloride, with p-toluene sulfonamide in the presence of dirhodium (II, III)
caprolactamate and potassium carbonate (Scheme 7).
OCH3

OCH3

CH3

CH3

Rh2(II,III)(Capy)4
K2CO3 , p-toluene sulfonamide

H
H3COOC

H

CH3

H3COOC

17

CH3

18
Scheme 7 : Formation of compound 18
22

N
Ts

1

The crystals that were obtained were yellow and the m.p. was 80oC. The IR, H13

NMR, C-NMR, HRMS and MS spectra of compound 18 are shown in Figures 21, 22,
23, 24 and 25 respectively.

Figure 21 : IR Spectrum of Compound 18
-1

Compound 18 showed strong absorptions at 1151 and 1319 cm indicating a sulfone
group. A carbonyl group was shown to be present by a strong absorption band at
-1

1720 cm-1, along with an ether moiety at 1209 cm . Absorptions for the aromatic ring
-1

were also present at 1609, 1496 and 1450 cm .

23

(17)

1

Figure 22 : H-NMR Spectrum of Compound 18
1

Examination of the H-NMR spectrum of compound 18 (Figure 22) showed that the
alkene protons that were present in starting compound 17 has disappeared. The spectrum
also showed the appearance of two multiplets at δH 3.44 (m, 1H) and 4.04 (m, 1H) ppm
representing two hydrogen atoms on the carbons in the aziridine ring. Compound 18
showed a multiplet at δH 6.98 (2H) and 7.76 (2H) ppm for the ortho and para protons on
24

the tosyl aromatic ring, respectively, and a singlet at δH 2.41(3H) ppm for the para
substituted methyl.

17

13

Figure 23 : C-NMR Spectrum of Compound 18

Examination of the

13

C-NMR of compound 18 showed 23 (three being similar) carbon

peaks all of which had shifted downfield. The disappearance of two chemical shifts at
127.3 and 125.1 ppm (Figure 23) that were present in starting compound 17, and the
appearance of two peaks at and 43.2 and 43.8 ppm (18), representing the C-6 and C-7
25

alkene bond being broken, hence supporting the assumption that the aziridine ring had
been formed successfully. The tosyl aromatic ring introduced seven new carbons, with
peaks at 25 (para-methyl group), 121.6 (2C), 130.9 (2C), 136 and 144 ppm.

Figure 24 : HRMS of Compound 18

The HRMS spectrum of compound 18 (Figure 24) showed a molecular ion at 469.1922
for a molecular formula of C26H31NO5S.
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Figure 25 : Mass Spectrum of Compound 18
+

The mass spectrum of compound 18 (Figure 25) displayed the molecular ion as [M+1] at
+

470.2. The peak at m/z 392.2 can be represented as [M-77] and is consistent with the
loss of two methoxy groups and a methyl group. The peak at m/z 302.0 is represented as
methyl-O-methyl podocarpate ion formed as a result of the cleavage of the C-6 and C-7
+

bonds to nitrogen. The [M-315] ion is due to the further fragmentation gives rise to the
peak at m/z 154.0 (Figure 26).
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Figure 26: Possible Fragmentations of Compound 18
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Therefore compound 18 can be assigned the structure shown in Figure 27.

OCH3

N
H3COOC

O
S
O

Figure 27 : Structure of Compound 18

The next part of this work involved an attempt to prepare novel derivatives of
aziridine 18 utilizing nucleophilic ring opening reactions as previously mentioned. The
general reaction conditions utilized mixing 0.50 mmol of aziridine 18 with 0.55 mmol of
the appropriate nucleophile and 0.05 mmol tri-n-butylphosphine in dry toluene, under
nitrogen gas. This mixture was stirred for 24 hr at 110oC under reflux. The solvent was
removed by evaporation invacuo and the crude product was purified using flash
1

chromatography. The structure of each derivative was elucidated by IR, H-NMR,
13

C-NMR, MS, and HRMS spectroscopy as described in the following.

The first nucleophile that was utilized for this ring opening was phenol. Thus
novel aziridine 18 was allowed to react with phenol, in the presence of catalytic amounts
29

of tri-n-butylphosphine to yield white crystals of derivative 19 in 90% yield with m.p.
o

1

160.5 C. The IR, H-NMR,

13

C-NMR, HRMS and MS spectra of compound 17 are

shown in Figures 28, 29, 30, 31 and 32, respectively.
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18

19
Scheme 8 : Formation of Phenol derivative 19

Figure 28 : IR Spectrum of Compound 19
30

-1

Compound 19 showed strong IR absorptions (Figure 28) at 1155 and 1326 cm

indicating a sulfone group. A carbonyl group was shown to be present by a strong
-1

-1

absorption band at 1700 cm along with absorption at 1211 and 1230 cm which are
consistent with the presence of ether moieties. Absorptions for the aromatic ring were
-1

also present at 1609, 1507 and 1454 cm .

18

1

Figure 29 : H-NMR Spectrum of Compound 19

31

The 1H-NMR of compound 19 in C6D6 is shown in Figure 29. Three new aromatic
multiplets appeared at δH 6.54 (2H), 6.89 (1H) and 7.22 (2H) ppm these represented the
phenoxy moiety. Integration for an N-H (b, 1H) at δH 2.04 (s, 1H) ppm was seen, but was
not visible as it was hidden under other peaks at δH 2.03. The protons for the methoxy
groups appeared at δH 3.16 (s, 3H) and 3.34 (s, 3H) ppm. The chemical shift for the
protons on the C-6 and C-7 carbons shifted to δH 4.04 (m, 1H) and 5.19 (m, 1H) ppm,
respectively.

(18)

13

Figure 30 : C-NMR Spectrum of Compound 19
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13

Examination of the C-NMR spectrum (Figure 30) of compound 19 showed a shift
downfield for the two peaks at 40 and 44 ppm (shifted to 48 and 78 ppm) which
represents two aliphatic methyls. Additional aromatic signals appeared at 118 (2C),
130(2C), 133 and 158 ppm, which correspond to the aromatic ring carbons from the
phenoxy group.

Figure 31 : HRMS of Compound 19

The HRMS spectrum (Figure 31) of compound 19 shows a molecular ion at 563.2256 for
a molecular formula of C32H37NO6S.

Figure 32 : Mass Spectrum of Compound 19
33

+

The mass spectrum of compound 19 displayed the molecular ion as the [M+1] peak at
+

m/z 564.2 (Figure 32). [M-171] is represented as the loss of the toluene sulfonylamine
group by breaking of the C-N bond at C-6 shown at m/z 392.1. The peak at m/z 302.1 is
represented as methyl-O-methyl podocarpate ion as a result of the cleavage of the C-6
and C-7 bonds to the toluene sulfonylamine and phenoxy groups. The peak at m/z 460.1
+

is represented as [M-103] and is consistent with the loss of a methoxycarbonyl, a methyl
and ethene groups. Further fragmentation gave the base peak at m/z 154.0, represented as
+

[M-409] (Figure 34).

Therefore compound 19 can be assigned the structure shown in Figure 33.
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Figure 33 : Structure of Compound 19
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Figure 34: Possible Fragmentations of Compound 19
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The second ring opening reaction of aziridine 18 involved the use of the
nucleophile, m-chlorophenol, in the presence of catalytic amounts of tri-n-butylphosphine
o

1

to yield yellow crystals of derivative 20 in 95% yield with m.p. 167 C. The IR, H-NMR,
13

C-NMR, HRMS and MS spectra of compound 20 are shown in Figures 35, 36, 37, 38

and 39, respectively.
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Scheme 9 : Formation of m-chlorophenol derivative 20

Figure 35 : IR Spectrum of Compound 20
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The IR spectrum (Figure 35) of compound 20 showed strong absorptions at 1158 and
-1

-1

1333 cm which indicated a sulfone group. A strong absorbance at 819 cm indicated
the presence of chlorine. A carbonyl group was shown to be present by a strong
-1

absorption band at 1726 cm along with ether moiety indicated by the absorption at 1225
-1

-1

cm . Absorptions for the aromatic ring were also present at 1598, 1495 and 1454 cm .
-1

1, 3 disubstitution of the aromatic ring was shown by peaks at 808, 899 and 1141 cm .

18

Figure 36 : 1H-NMR Spectrum of Compound 20
37

1

Figure 36 shows the H-NMR spectrum of compound 20. A slight shoulder was seen at

δH 2.05 (s, 1H) ppm, this represents the N-H (b, 1H). The protons for the methoxy groups
appeared at δH 3.16 (s, 3H) and 3.34 (s, 3H) ppm. The chemical shift for the protons on
the C-6 and C-7 carbons moved to δH 4.04 (m, 1H) and 5.24 (m, 1H) ppm respectively.
Four new aromatic protons appeared at δH 6.36 (1H), 6.78 (m, 1H), 6.88 (m, 1H) and
7.60 (m, 1H) ppm that could be assigned to the chlorophenoxy group.

18

Figure 37 : 13C-NMR Spectrum of Compound 20
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13

Examination of the C-NMR spectrum (Figure 37) of compound 20 indicated two peaks
in the aliphatic region of the starting material had shifted from 40 and 43 ppm to 48 and
78 ppm, respectively. Six new aromatic peaks were appeared 116, 118, 132, 133, 133.5
and 159 ppm, which could be assigned to the aromatic ring carbons of the
m-chlorophenoxy group.

Figure 38 : HRMS of Compound 20

Figure 39 : Mass Spectrum of Compound 20
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The HRMS spectrum of compound 20 (Figure 39) shows a molecular ion at 597.2256 for
a molecular formula of C32H36NO6SCl. The mass spectrum of compound 20 displayed
+

the [M+1] peak at m/z 598.2 (Figure 37). The peak at m/z 470.2 is represented as [M+

+

127] and is consistent with the loss of the m-chlorophenoxy group. [M-205] is shown
as 392.2 as the loss of the chlorine and toluene sulfonylamine groups. The peak at m/z
302.1 is represented as methyl-O-methyl podocarpate ion as a result of the cleavage of
the C-6 and C-7 bonds to the toluene sulfonylamine and m-chlorophenoxy groups.
+

Further fragmentation gave the base peak at m/z 154.0, represented as [M-443] (Figure
41).

Therefore compound 20 can be assigned the structure shown in Figure 40.
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Figure 40 : Structure of Compound 20
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Figure 41 : Possible Fragmentation of Compound 20
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In summary the reaction of aziridine derivative 18 with phenols gave ether
sulfonamide derivatives of podocarpic acid in high yields (74.5 % for compound 20 and
77 % for compound 19). Thus three novel compounds (18, 19 and 20) have been
synthesized from podocarpic acid. These compounds will be submitted to the National
Cancer Institute against 60 cancer cell lines. They will also be submitted to the National
Institute for Allergies, Infections, and Diseases for bioevaluation against human
tuberculosis. Thus this work may result in a new drug lead useful for the treatment of
human cancer or tuberculosis.
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3.0. EXPERIMENTAL
3.1. Instruments Used

All melting points were obtained using a MEL-TEMP apparatus, IR spectra were
recorded on a Perkin Elmer Spectrum One Spectrometer (Perkin Elmer Spectrometer)
and Perkin Elmer Spectrum 100 FTIR Spectrometer (Perkin Elmer FTIR Spectrometer),
1

H and

13

C NMR spectra were obtained on a Varian Mercury 300MHz spectrometer

using CDCl3 or C6D6 as the solvent, and HRMS spectra were obtained from the
University of Nebraska Chemistry Department.

3.2. Preparation of Methyl-O-methylpodocarpate (10)

60 g of recrystallized podocarpic acid (1) were weighed in a 400 mL beaker and
60 g of ice were added to it. 60 mL of methanol were then added to the beaker with
stirring. 30 g of sodium hydroxide pellets were then added to this and the mixture was
allowed to stir for 2 hrs. This solution was cooled to 150C in an ice bath, and then 51 mL
of dimethyl sulfate was added drop by drop over a period of 1.5 hrs. After the reaction
had finished as shown by solidification of the solution, 15 mL of methanol were added
and the solution was stirred for a 30 minutes. 120 mL of water was added to the reaction
mixture and this was then vacuum filtered. Recrystallization of the crude product in
methanol yielded 45 g (78%) of a white solid methyl-O-methylpodocarpate (10) with an
m.p. of 127.00C. IR (KBr): 1725, 1500 and 1450 cm-1. 1H-NMR (Mercury 300MHz)
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(CDCl3): 6.9 (d), 6.75 (s), 6.6 (d), 3.8(s), 3.6(s), 2.75 (m), 2.2 (m), 1.9 (m), 1.55 (m), 1.4
(m), 1.23 (m), 1.2(s), 1.15 (m), 1.05 (m), 1.00 (s) ppm.

3.3. Preparation of Methyl-O-methyl-7-ketopodocarpate (15)

40 g of methyl-O-methylpodocarpate (10) were dissolved in 400 mL of acetic
acid. 37.6 g of chromium trioxide were then dissolved in 320 mL of acetic acid-80 mL
water solution that was then added to the ester solution with stirring for 10 minutes. This
was then allowed to stand overnight at room temperature. The precipitate was removed
by filtration and was washed with water to yield 32 g (90%) of methyl-O-methyl-7ketopodocarpate (15) as yellow crystals with m.p. 1220C. IR (KBr): 1700 and 1625 cm-1.
1

H-NMR (Mercury 300MHz) (CDCl3): 0.98 (s), 1.2 (s), 3.68 (s), 3.86 (s), 6.66 (m) and

7.83 (d)

3.4. Preparation of Methyl-O-methyl-7-hydroxypodocarpate (16)

30 g of methyl-O-methyl-7-ketopodocarpate (15) were dissolved in 52 mL of
tetrahydrafuran and 60 mL of ethanol (95%). After 6 g of sodium borohydride were
dissolved in 24 mL water and 9mL ethanol (95%), the solution was slowly added to the
ketoester solution over a 10 minute period. The resulting mixture was then stirred 24 hrs
at room temperature, after which the precipitate was removed by filtration. Evaporation
of the filtrate solution in vacuo gave a light green syrup. This syrup was then dissolved in
75 mL of ether, followed by the addition of 10 mL of aqueous sodium chloride (5%). The
aqueous layer was extracted three times with 75 mL of ether. All the ether extracts were
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combined and washed twice with 60 mL portions of aqueous sodium chloride (5%), dried
with anhydrous magnesium sulfate, gravity filtered, and evaporated in vacuo. 26.2 g
(80%) of methyl-O-methyl-7-hydroxypodocarpate (16) were obtained by recrystallization
in methanol as white crystals with m.p. of 1020C. IR (KBr): 3500, 1715, 1610, 1575 cm-1.
1

H-NMR (Mercury 300MHz) (CDCl3) : 0.88 (s), 1.32 (s), 3.70 (s), 3.82 (s), 4.51 (m),

6.83 (m) ppm.

3.5. Preparation of Compound 17

20.0 g of compound (16) were dissolved in 12.5 mL of dihydropyran, and 1.25 g
of p-toluenesulfonic acid were added to the reaction flask. This was then heated at reflux
for 10 hours. The resulting mixture was allowed to cool, and was extracted with 500 mL
of ether. The organic phase was first washed with water (25 mL), then 5% aqueous
sodium carbonate (25 mL), and then 25 mL more water, and finally dried over
anyhydrous magnesium sulfate. The oily liquid obtained by gravity filtration was rotary
evaporated and elution with petroleum ether and methylene chloride through a column
yielding compound (17) (85%) that was obtained in its pure form by rotary evaporation
for several hours. 17.5 g of compound (17) were obtained as light green crystals with a
1

melting point of 840C. IR (KBr): 2950, 1720 and 1600 cm-1. H-NMR (Mercury
300MHz) (CDCl3) : 0.86 (s), 1.35 (s), 3.75 (s), 3.88 (s), 6.38 (m), 6.67 (d), 6.51 (s) and
6.90 (s), 7.25 (s) ppm.
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3.6. Preparation of Aziridine Derivative 18

1.6 g of alkene (17) were placed in a 25 mL round bottom flask equipped with a
stir bar. To this 1.3g of p-toluenesulfonamide, 0.002g of Doyle’s Catalyst (Tetrakis
dirhodium caprolactamate), 1.6 g of potassium carbonate and 15 mL of methylene
chloride were added. The resulting mixture was then stirred for 10 minutes. To this
solution 1.1 g of N-bromosuccinimide was added in one portion and as a result a color
change of the solution from light purple to red was observed. A septum was used to seal
the flask with the inclusion of air. After 24 hours of stirring, the mixture was evaporated
in vacuo and the solid was redissolved in a 25 : 75 ethyl acetate : hexane mixture. This
mixture was separated by column chromatography using 63–200 mesh silica gel, yielding
1.4 g (85% yield) of the pure aziridine 18. The m.p. of compound 18 was found to be
800C. IR (Perkin Elmer FTIR Spectrometer): 2933, 1720, 1609, 1575, 1496, 1319, 1304,
-1

1279, 1238, 1209, 1151, 1089, 1070, 1039, 981, 898, 872, 833, 813, 772, 708, 676 cm .
1

H-NMR (Mercury 300MHz) (C6D6): 0.89 (s), 1.20 (s), 1.48 (s), 1.6 (s), 1.77 (d), 2.0

(m), 2.41 (s), 3.44 (d), 3.48 (s), 3.74 (s), 4.04 (m), 4.65 (m), 6.58 (d), 6.81 (d), 6.88 (d),
13

7.76 (m) ppm. C-NMR (Mercury 300MHz) (C6D6): 20, 22, 25, 29, 38, 38.5, 41, 43, 44,
49, 52, 55, 111, 111, 112, 121.5, 128, 130, 131, 136, 144, 150, 160, 178 ppm. MS:

3.7. Preparation of Phenol Derivative 19

0.2468 g of aziridine derivative 18 was placed in a round bottom flask while
stirring in toluene under a nitrogen atmosphere. To the resulting solution, 1 mL of tri-n46

butylphosphine and 0.083 g of phenol were added. The resulting mixture was stirred at
reflux (1000C) for 24 hours (at which time the TLC showed that no reactants remained)
and then the flask was allowed to cool to room temperature. The solvent was then
removed in a vacuum and flash chromatography using 63-200 mesh silica gel to purify
the crude product. After vacuum removal of the solvent from the eluent, phenol
derivative 19 was obtained as 0.24 g (77% yield) of light yellow crystals that melted at
160.50C. IR (Perkin Elmer FTIR Spectrometer): 3120, 2948, 1727, 1700, 1648, 1609,
1591, 1507, 1489, 1454, 1354, 1326, 1314, 1293, 1259, 1230, 1211, 1155, 1104, 1086,
1064, 1037, 876, 976, 963, 937, 845, 819, 806, 765, 735, 710, 694, 663 cm-1. 1H-NMR
(Mercury 300MHz) (C6D6) : 0.89 (s), 1.20 (s), 1.48 (s), 1.6 (s), 1.77 (d), 2.0 (m), 2.04 (s),
2.41 (s), 3.44 (d), 3.16 (s), 3.34 (s), 4.04 (m), 5.19 (m), 6.54 (d), 6.58 (d), 6.81 (d), 6.88
(d), 6.89 (d), 7.22 (m), 7.76 (m) ppm
13

C-NMR (Mercury 300MHz) (C6D6): 21, 22, 26, 28, 38.5, 46, 48, 50, 53, 55.5, 78,

111.5, 112, 118 (2C), 122.5, 128, 129, 130 (2C), 133, 136, 143, 148.5, 158, 160, 179
ppm.

3.8 Preparation of m-Chlorophenol Derivative 20

0.5054 g of aziridine derivative 18 was was placed in a round bottom flask whilst
stirring in toluene (2 mL) under a nitrogen atmosphere. To this solution 1 mL of tri-nbutylphosphine and 0.1602 g of m-chlorophenol were added. The resulting mixture was
stirred at reflux (1000C) for 24 hours (at which time the TLC showed that no reactants
remained) and then the flask was allowed to cool to room temperature. The solvent was
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removed in a vacuum and flash chromatography using 63-200 mesh silica gel was used to
purify the crude product. After vacuum removal of the solvent from the eluent, mchlorophenol derivative 20 was obtained as 0.48 g (74.5% yield) of light yellow crystals
that melted at 1670C. IR (Perkin Elmer FTIR Spectrometer): 3181, 2937, 1726, 1711,
1652, 1598, 1495, 1454, 1378, 1350, 1333, 1280, 1249, 1225, 1174, 1158, 1066, 1034,
-1

998, 985, 899, 853, 819, 808, 770, 731, 711, 683 cm .
1

H-NMR (Mercury 300MHz) (C6D6) : 0.89 (s), 1.20 (s), 1.48 (s), 1.6 (s), 1.77 (d), 2.0

(m), 2.05 (s), 2.41 (s), 3.16 (s), 3.34 (s),3.44 (d), 4.04 (m), 5.24 (m), 6.36 (s), 6.58 (d),
6.78 (m), 6.81 (d), 6.88 (d), 6.88 (m), 7.60 (m), 7.76 (m) ppm. 13C-NMR (Mercury
300MHz) (C6D6): 21, 22, 26, 28, 38.5, 46, 48, 50, 53, 55.5, 77, 111.5, 112, 116, 118,
122.5, 128, 129, 132, 133, 133.5, 136, 143, 148.5, 159, 160, 179 ppm.
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